LIST OF FIGURES

Figure 1.1 Normal hematopoiesis in bone marrow endosteal and the involvement of niche stromal cells (courtesy www.php.med.unsw.edu.au).................................................................3

Figure 1.2 Transcription factors in Haematopoiesis. The stages at which hematopoietic development is blocked in the absence of a given transcription factor, as determined through conventional gene knockouts, are indicated by red bars. The factors depicted in black have been associated with oncogenesis. Those factors in light font have not yet been found translocated or mutated in human/mouse hematologic malignancies. Abbreviations: LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term hematopoietic stem cell; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progenitor; RBCs, red blood cells. This figure is adopted from (Orkin and Zon 2008) ....5

Figure 1.3 Canonical Wnt Pathway A. In the absence of WNT, β-catenin undergoes proteosomal degradation within the cytoplasm by ‘multi-protein destruction complex’ (MDR) of adenomatous polyposis coli (APC), axin, glycogen synthase 3β (GSK-3β) and casein kinase 1α (CK1α) which phosphorylates β-catenin. This leads to ubiquitination and subsequent proteosomal degradation. B. When WNT binds to frizzled and low density lipoprotein receptor related proteins 5 or 6 (LRP) receptor, dishevelled (Dsh) protein inactivates GSK-3β and the β-catenin accumulates in the cytoplasm and finally translocated along with plakoglobin to the nucleus. Along with cyclic AMP response element-binding protein (CBP), β-catenin facilitates transcriptional activation of lymphocyte enhancer binding actor (LEF)/T cell factor (TCF) and results in the target gene transcription. The data is adopted from (Khan et al 2006)..................................................8

Figure 1.4 Notch signalling pathway. a) Signal initiation by the binding of Notch ligand. b) ADAM metalloproteases cleavage. c) Cleavage of Notch by γ-secretase. d) Nuclear translocation of Notch intracellular domain (NCID). e) Transcriptional activation of target genes. f) Expression of target proteins .................................................................10

Figure 1.5 Different steps involved in the trafficking of leukocytes through the blood vessel ........................................................................................................................................31

Figure 1.6 The yeast-two-hyrid system. Many eukaryotic transcriptional activators have two distinct functional domains, one that binds to a promoter DNA sequence (BD) and one that activates transcription (AD). In the two-hybrid assay, two plasmids are constructed. The first plasmid encodes a bait protein fused to a BD. The second plasmid encodes a target protein (or proteins encoded by an expression library) fused to an AD. The two fusion constructs are then coexpressed in the same cell. If the bait- and target proteins interact the two halves (BD and AD) will be brought together forming an intact and functional transcriptional activator. The intact transcriptional activator is then able to induce transcription of a downstream reporter gene. This figure is adopted from (Berggård et al., 2007)........................................................................................................34
Figure 1.7 Schematic representation of far-western approach.................................36

Figure 3.1 Silver-stained 2-DE of JM-1 lysate proteins run without subjecting to any treatment. A) 200mg B) 300mg. Arrows represent complexes that failed to run into the gel.................................................................56

Figure 3.2 Representative 2-DE of JM1 lysate proteins precipitated with MAc (A), acetone (B) and PCI alcohol (C). Arrows indicate the spots that have migrated to identical pI and Mr across gels despite different precipitation strategies ...........................................58

Figure 3.3 Comparison between MAc (A), acetone (B) and PCI alcohol (C) patterns of proteins at highMr regions of the gels. Note the presence of higher numbers of protein spots in boxes 1’, 2’ and 3’ (B) from acetone precipitate compared with MAc [boxes 1, 2 and 3, (A)] and PCI alcohol [boxes 1”, 2” and 3”, (C)]. Arrowheads represent differential enrichment of representative proteins between different protein precipitation strategies mentioned above. Arrows show few representative proteins that have identical migration patterns irrespective of the different precipitation strategies shown.................................59

Figure 3.4 Evaluation of the extent of DNA removal from cell lysates using centricon method. (A) Histogram representing the DNA content expressed in 260/280 ratio in the initial lysate (JM-1 homogenate) and in the flow through following each wash. Note the increased 260/280 ratios in washes. (B) Milligram DNA per milligram protein in various protein processing strategies used in the study. Note the statistically significant p-values when centricon strategy of protein processing is compared with other processing strategies and the initial homogenate (H).................................................................61

Figure 3.5 Representative 2-DE of JM-1 lysate proteins processed by centricon method (A) versus ethanol precipitation method (B). Arrows indicate the spots that have migrated to identical pI and Mr across gels despite different ways of protein enrichment strategy followed..................................................................................61

Figure 3.6 A comparison of proteins patterns between 50 and 250 kDa pI toMr co-ordinates of silver stained representative 2-DE gels in ethanol and centricon strategy of protein enrichment. Note the absence of many protein spots in boxes 1, 2 and 3 in ethanol precipitation compared with centricon method [boxes 1’, 2’ and 3’, (B)]. Arrowheads represent proteins that are enriched with ethanol precipitation strategy compared with centricon method. On the other hand, arrows show some other proteins that are less enriched by ethanol precipitation compared with centricon method.................................62

Figure 3.7 Validation of biotinylation of CSF proteins by comparing the SDS-PAGE and Strep-HRP probing. (A) Silver stained 1D profiled biotinylated CSF proteins; (B) The extent of biotinylation of 1D profiled CSF proteins after strep-HRP probing. The double headed arrow indicates the proteins that are seen in the silver stained gel that are getting biotinylated and stained with streptavidin-HRP on the blot.................................69
Figure 3.8 Schematic representation of how comparison of CSF reactivity to lymphoblastic proteins on the 2D blot among different patients in a sequential manner is carried out in the current study. CSF reactivity of sequential samples like Presentation/CNS involvement and following treatment from the same patient were compared first and then compared the reactivity pattern between patients. The proteins that showed differential reactivity in a consistent way are marked with arrows and arrowheads. Those proteins that show consistent reactivity pattern across different patients at diagnosis/presentation, remission and relapse were selected for further validation. A, B and C are representation for sequential samples from each patients...

Figure 3.9 Comparison of CSF reactivity of a set of ALL patients at different time points towards proteins of lymphoblastic origin on the 2D blot. The protein spots marked through 1-4 showed consistent pattern of reactivity to lymphoblastic proteins and selected for mass spectrometric analysis. The positions of spots 1-4 were marked in the Coomassie stained gel also (yellow colour arrows). The position of GAPDH is marked with arrow head in each blot and the gel...

Figure 3.10 Representation of quantified CSF reactivity to lymphoblastic proteins (spot 1-4) on the 2D blot under presentation/CNS relapse and remission conditions...

Figure 3.11 Cloning and expression strategy for PFDN5α/CIP29/ECH1/PRDX6 in bacterial expression system...

Figure 3.12 Cloning and expression of proteins identified by mass spectrometry in bacterial expression system A. Isolated plasmids of pCMV6-XL5-PFDN5/CIP29/ECH1/PRDX6 and pET28a were run on 1% agarose gel; B. Gel purified PFDN5/CIP29/ECH1/PRDX6 after restriction digestion of pCMV6-XL5-PFDN5/CIP29/ECH1/PRDX6 with EcoRI and NotI. All the purified fractions were marked with their respective sizes. Then the genes were ligated to pET28a vector using T4 DNA ligase; C. The plasmid pET28a containing PFDN5/CIP29/ECH1/PRDX6 was isolated and digested with EcoRI & NotI. Presence of two bands, i.e., one in the insert gene size and the other one of vector size, indicates the presence of respective genes in pET28a vector; D. The proteins were expressed in bacteria and the lysates were run on SDS-PAGE (15% gel for PFDN5α and 12% gel for CIP29, ECH1 and PRDX6) and then stained the gel with silver. The expressed proteins were finally confirmed by probing with antibody specific to the protein following purification of the protein using Ni-NTA histidine affinity column. The position of each protein marked with the arrowhead...

Figure 3.13 CSF reactivity of different ALL patients towards purified PFDN5α on 1D blot. The double headed arrows indicate the position of protein...

Figure 3.14 CSF reactivity of different ALL patients towards purified CIP29, ECH1 and PRDX6 on the 1D blot. The position of each protein marked with arrowhead...
**Figure 3.15** Comparison of CSF reactivity patterns of sequential samples from patients with CNS involvement. From the graph it is clear that the reactivity to PFDN5α is comparatively low i.e., below 0.05OD when there is CNS involvement and the reactivity become high i.e., above 0.05OD when the patient’s prognosis is good. The 0.05OD cut off level is marked with blue line in the figure. Note that though all the patients clinically diagnosed having CNS leukemia showed low reactivity, the subsequent sequential samples during treatment also showed low reactivity below 0.05 OD. This is because they are in a recovery phase of improvement from CNS leukemia though clinically considered as remission (Table 3.4 and 3.9) based on CNS cytology showing no blast cells. .................................................................94

**Figure 3.16** Comparison of quantitative average of CSF reactivity at CNS positive and remission condition (p-value is 0.022). Note the low CSF reactivity seen in CNS leukemia patients compared to remission status where there is no CNS leukemia..........95

**Figure 3.17** Comparison of CSF reactivity pattern of sequential samples from patients without CNS involvement. From the graph it is clear that the reactivity to PFDN5α remained above 0.05 cut off (red line in figure) except for patient 9, 12 and 13. In patients 9, 12 and 13 the values are below 0.05OD and is comparable to that of samples with CNS involvement suggesting the possibility of developing CNS disease.. ...........96

**Figure 3.18** CSF reactivity of control samples to PFDN5α. The CSF samples used as control for the analysis is collected from patients with pyrexia, Down’s syndrome, Type II diabetics and Vascular headache.................................................................97

**Figure 4.1** Protein interaction network of PFDN5α. The proteins represented in blue have role in metastasis when down regulated .................................................................103
LIST OF TABLES

Table 1.1 Differentially expressed genes in pre B-ALL samples with ALL1/AF4, E2A/PBX1 and BCR/ABL gene translocations. The data is adopted from (Chiaretti et al, 2005) .....15

Table 3.1 Comparison of total number of protein spots in different sample preparation strategies..........................................................59

Table 3.2 Milligram proteins/mg million cells from three different samples processed by centricon and ethanol protein processing strategies .................................................62

Table 3.3 The number of common and unique spots seen in both centricon and ethanol preparations ...............................................................................................................63

Table 3.4 The demographic details of the patient samples used for far-western analysis and later on for ELISA quantification ...............................................................70

Table 3.5 Quantification of CSF reactivity to protein spots 1-4 using Image J software. The value for each spot shown in the table is normalised with GAPDH .......................75

Table 3.6 Quantified values selected for graphical representation of spot 1-4 under presentation/CNS relapse and remission conditions in 4 different patients. The sequential sample ID is given in the brackets of each value ........................................76

Table 3.7 Protein ID obtained by mass spectrometric analysis. Spots which showed differential reactivity to ALL-CSF were cut out from the equivalent coomassie stained gel and analysed at National Centre for Biological Sciences, Bangalore and Amrita Centre for Nanosciences and Molecular Medicine, Kochi by ESI Q-TOF mass spectrometry ..........................................................77

Table 3.8 Functions and reported role in cancer of mass spectrometrically identified proteins. Reports related to leukemia are highlighted in the table. .........................78

Table 3.9 Details of patient CSF samples used for quantification of reactivity to PFDN5α by ELISA. In addition to these samples, the samples mentioned in table 3.4 also used for ELISA quantification. Patients who are negative for CNS involvement are called CNS negative and positive for CNS involvement are called CNS positive. This classification is based on the cytological analysis of CSF samples..........................................................88

Table 3.10 ELISA quantification data of CNS positive patients. These values are represented in the graph in figure 3.15 .............................................................................93

Table 3.11 ELISA quantification values of CNS positive and Remission samples of patients with CNS involvement selected for calculating the quantitative average. The sequential sample ID is given in the brackets of each value. The average value of these two clinical situations is represented in the graph in figure 3.16. .............................................94
Table 3.12 ELISA quantification data of patients without CNS involvement. These values are represented in the graph in figure 3.17. Presentation in this table indicates the diagnosis sample. 

96